Christina Murphy, | |
559 Zor Shrine Pl, Madison, WI 53719-2068 | |
(608) 833-0123 | |
Not Available |
Full Name | Christina Murphy |
---|---|
Gender | Female |
Speciality | Behavior Analyst |
Location | 559 Zor Shrine Pl, Madison, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003207200 | NPI | - | NPPES |
3855-125 | Other | WI | PROFESSIONAL COUNSELOR LISCENCE |
223-140 | Other | WI | BCBA LICENSE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YP2500X | Counselor - Professional | 3855-125 (Wisconsin) | Secondary |
103K00000X | Behavior Analyst | 223-140 (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
Christina Murphy, 320 N Elmridge Ave, Brookfield, WI 53005-6117 Ph: () - | Christina Murphy, 559 Zor Shrine Pl, Madison, WI 53719-2068 Ph: (608) 833-0123 |
News Archive
As part of a groundbreaking global effort to test several million people for HIV in conjunction with this year's observation of World AIDS Day on Tuesday, December 1st, AIDS Healthcare Foundation (AHF), the largest global AIDS organization, is spearheading and coordinating the ‘Testing Millions' campaign. The campaign, which has been organized by AHF in coalition with hundreds of global partners from 52 countries around the world, is mobilizing non-governmental organizations (NGOs), local and national governments, international relief agencies, faith-based organizations and civil society to participate.
Medical oncologists across the nation want to know whether a certain drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it's in an advanced stage.
A new study by a Mayo Clinic neurologist finds that, overall, motion pictures inaccurately represent the comatose state. Findings will appear in the May issue of the journal Neurology.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the third quarter of 2009. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.01 per share for the thirteen week period ended October 3, 2009.
› Verified 4 days ago